PubMed:19891556
Annnotations
LitCoin-entities
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| 6773 | 0-11 | ChemicalEntity | denotes | Clopidogrel | MESH:D000077144 |
| 6774 | 123-134 | ChemicalEntity | denotes | clopidogrel | MESH:D000077144 |
| 6775 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | MESH:D003324 |
| 6776 | 195-203 | OrganismTaxon | denotes | patients | NCBITaxon:9606 |
| 6777 | 283-291 | OrganismTaxon | denotes | patients | NCBITaxon:9606 |
| 6778 | 343-354 | ChemicalEntity | denotes | Clopidogrel | MESH:D000077144 |
| 6779 | 412-419 | GeneOrGeneProduct | denotes | CYP2C19 | NCBIGene:1557 |
| 6780 | 521-528 | GeneOrGeneProduct | denotes | CYP2C19 | NCBIGene:1557 |
| 6781 | 606-617 | ChemicalEntity | denotes | clopidogrel | MESH:D000077144 |
| 6782 | 805-816 | ChemicalEntity | denotes | clopidogrel | MESH:D000077144 |
| 6783 | 870-877 | GeneOrGeneProduct | denotes | CYP2C19 | NCBIGene:1557 |
| 6784 | 890-901 | ChemicalEntity | denotes | clopidogrel | MESH:D000077144 |
| 6785 | 1053-1060 | GeneOrGeneProduct | denotes | CYP2C19 | NCBIGene:1557 |
| 6786 | 1119-1130 | ChemicalEntity | denotes | clopidogrel | MESH:D000077144 |
LitCoin-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-96 | Sentence | denotes | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. |
| T2 | 97-252 | Sentence | denotes | Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. |
| T3 | 253-342 | Sentence | denotes | However, approximately 25% of patients experience a subtherapeutic antiplatelet response. |
| T4 | 343-447 | Sentence | denotes | Clopidogrel is a prodrug that undergoes hepatic biotransformation by CYP2C19 into its active metabolite. |
| T5 | 448-758 | Sentence | denotes | Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events. |
| T6 | 759-959 | Sentence | denotes | Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response. |
| T7 | 960-1149 | Sentence | denotes | Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness. |
LitCoin_Mondo
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | 0005010 |
| T2 | 383-390 | DiseaseOrPhenotypicFeature | denotes | hepatic | 0002251 |
LitCoin-GeneOrGeneProduct-v0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 162-166 | GeneOrGeneProduct | denotes | care |
| T2 | 262-275 | GeneOrGeneProduct | denotes | approximately |
| T3 | 412-419 | GeneOrGeneProduct | denotes | CYP2C19 |
| T4 | 429-435 | GeneOrGeneProduct | denotes | active |
| T5 | 521-528 | GeneOrGeneProduct | denotes | CYP2C19 |
| T6 | 544-552 | GeneOrGeneProduct | denotes | carriers |
| T7 | 627-633 | GeneOrGeneProduct | denotes | active |
| T8 | 666-676 | GeneOrGeneProduct | denotes | activation |
| T9 | 860-866 | GeneOrGeneProduct | denotes | impact |
| T10 | 870-877 | GeneOrGeneProduct | denotes | CYP2C19 |
| T11 | 1053-1060 | GeneOrGeneProduct | denotes | CYP2C19 |
| T12 | 1076-1084 | GeneOrGeneProduct | denotes | carriers |
| T13 | 1089-1094 | GeneOrGeneProduct | denotes | other |
LitCoin-GeneOrGeneProduct-v2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 412-419 | GeneOrGeneProduct | denotes | CYP2C19 |
| T2 | 521-528 | GeneOrGeneProduct | denotes | CYP2C19 |
| T3 | 860-866 | GeneOrGeneProduct | denotes | impact |
| T4 | 870-877 | GeneOrGeneProduct | denotes | CYP2C19 |
| T5 | 1053-1060 | GeneOrGeneProduct | denotes | CYP2C19 |
| T6 | 1089-1094 | GeneOrGeneProduct | denotes | other |
LitCoin-Disease-MeSH
| Id | Subject | Object | Predicate | Lexical cue | originalLabel |
|---|---|---|---|---|---|
| T1 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | D003324 |
LitCoin-GeneOrGeneProduct-v3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 412-419 | GeneOrGeneProduct | denotes | CYP2C19 |
| T2 | 521-528 | GeneOrGeneProduct | denotes | CYP2C19 |
| T3 | 870-877 | GeneOrGeneProduct | denotes | CYP2C19 |
| T4 | 1053-1060 | GeneOrGeneProduct | denotes | CYP2C19 |
LitCoin_Mondo_095
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | 0005010 |
LitCoin-MeSH-Disease-2
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | D003324 |
LitCoin-MONDO_bioort2019
| Id | Subject | Object | Predicate | Lexical cue | #label |
|---|---|---|---|---|---|
| T1 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | D003324 |
LitCoin-Chemical-MeSH-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 0-11 | ChemicalEntity | denotes | Clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
| T4 | 123-134 | ChemicalEntity | denotes | clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
| T7 | 343-354 | ChemicalEntity | denotes | Clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
| T10 | 606-617 | ChemicalEntity | denotes | clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
| T13 | 890-901 | ChemicalEntity | denotes | clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
| T16 | 1119-1130 | ChemicalEntity | denotes | clopidogrel | D000077144|http://purl.obolibrary.org/obo/CHEBI_37941|ChemicalEntity |
LitCoin-NCBITaxon-2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 195-203 | OrganismTaxon | denotes | patients |
| T2 | 283-291 | OrganismTaxon | denotes | patients |
LitCoin-training-merged
| Id | Subject | Object | Predicate | Lexical cue | #label | ID: |
|---|---|---|---|---|---|---|
| T16 | 1119-1130 | ChemicalEntity | denotes | clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T13 | 890-901 | ChemicalEntity | denotes | clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T10 | 606-617 | ChemicalEntity | denotes | clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T7 | 343-354 | ChemicalEntity | denotes | Clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T4 | 123-134 | ChemicalEntity | denotes | clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T1 | 0-11 | ChemicalEntity | denotes | Clopidogrel | ChemicalEntity|http://purl.obolibrary.org/obo/CHEBI_37941|D000077144 | |
| T39688 | 1053-1060 | GeneOrGeneProduct | denotes | CYP2C19 | ||
| T3 | 870-877 | GeneOrGeneProduct | denotes | CYP2C19 | ||
| T2 | 521-528 | GeneOrGeneProduct | denotes | CYP2C19 | ||
| T53702 | 412-419 | GeneOrGeneProduct | denotes | CYP2C19 | ||
| T27020 | 171-194 | DiseaseOrPhenotypicFeature | denotes | coronary artery disease | D003324 | |
| T78738 | 283-291 | OrganismTaxon | denotes | patients | ||
| T48935 | 195-203 | OrganismTaxon | denotes | patients |